EDGENE
- Biotech or pharma, therapeutic R&D
Edgene is revolutionizing genetic medicine with cutting-edge mitochondrial genome editing technology to address currently un-treatable mitochondrial diseases affecting 1 in 5,000 individuals. Leveraging proprietary TALED, HiFi-DdCBE, and ZFD base editing platforms, Edgene offers precise, disease modifying interventions for devastating conditions like LHON, Leigh syndrome, and MELAS. Unlike conventional gene therapies that only replacement of wildtype genes, Edgene’s technology directly repairs mitochondrial DNA mutations, setting a new standard for therapeutic innovation.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}